82 related articles for article (PubMed ID: 27363335)
1. A bispecific anti-ErbB2 antibody potently induces ErbB2 internalization and suppresses ErbB2-overexpressing tumor growth.
Zhang Y; Wang L; Chong X; Yu X; Meng Y; Dong J; Wang C; Wang H; Yang Y; Xia T; Zhao J; Li B
Biochem Biophys Res Commun; 2016 Sep; 477(4):755-760. PubMed ID: 27363335
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibody to ErbB2 overcomes trastuzumab resistance through comprehensive blockade of ErbB2 heterodimerization.
Li B; Meng Y; Zheng L; Zhang X; Tong Q; Tan W; Hu S; Li H; Chen Y; Song J; Zhang G; Zhao L; Zhang D; Hou S; Qian W; Guo Y
Cancer Res; 2013 Nov; 73(21):6471-83. PubMed ID: 24046294
[TBL] [Abstract][Full Text] [Related]
3. An anti-ErbB2 fully human antibody circumvents trastuzumab resistance.
Lu Q; Wang L; Zhang Y; Yu X; Wang C; Wang H; Yang Y; Chong X; Xia T; Meng Y; Wang Y; Lu C; Zhou L; Li B
Oncotarget; 2016 Oct; 7(41):67129-67141. PubMed ID: 27564098
[TBL] [Abstract][Full Text] [Related]
4. Combating acquired resistance to trastuzumab by an anti-ErbB2 fully human antibody.
Wang C; Wang L; Yu X; Zhang Y; Meng Y; Wang H; Yang Y; Gao J; Wei H; Zhao J; Lu C; Chen H; Sun Y; Li B
Oncotarget; 2017 Jun; 8(26):42742-42751. PubMed ID: 28514745
[TBL] [Abstract][Full Text] [Related]
5. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.
Wang S; Chen C; Meng Y; Hu S; Zheng L; Song J; Zhang D; Li B; Guo Y
Cancer Lett; 2012 Dec; 325(2):214-9. PubMed ID: 22789781
[TBL] [Abstract][Full Text] [Related]
6. Concurrent biological targeting therapy of squamous cell carcinoma of the esophagus with cetuximab and trastuzumab.
Yamazaki M; Yamashita Y; Kubo N; Yashiro M; Ohira M; Ako E; Tanaka H; Muguruma K; Sawada T; Hirakawa K
Oncol Rep; 2012 Jul; 28(1):49-54. PubMed ID: 22562413
[TBL] [Abstract][Full Text] [Related]
7. Synergistic antitumor effect of the anti-ErbB2 antibodies trastuzumab and H2-18 on trastuzumab-resistant gastric cancer cells.
Wang C; Wang L; Liang B; Zhou B; Sun Y; Meng Y; Dong J; Chen L; Li B
Oncol Lett; 2021 May; 21(5):400. PubMed ID: 33777223
[TBL] [Abstract][Full Text] [Related]
8. Enhanced antitumor activity of trastuzumab emtansine (T-DM1) in combination with pertuzumab in a HER2-positive gastric cancer model.
Yamashita-Kashima Y; Shu S; Harada N; Fujimoto-Ouchi K
Oncol Rep; 2013 Sep; 30(3):1087-93. PubMed ID: 23783223
[TBL] [Abstract][Full Text] [Related]
9. Combined SRC inhibitor saracatinib and anti-ErbB2 antibody H2-18 produces a synergistic antitumor effect on trastuzumab-resistant breast cancer.
Wang L; Yu X; Dong J; Meng Y; Yang Y; Wang H; Wang C; Zhang Y; Zhao Y; Zhao J; Wang H; Lu C; Li B
Biochem Biophys Res Commun; 2016 Oct; 479(3):563-570. PubMed ID: 27666484
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab in combination with trastuzumab shows significantly enhanced antitumor activity in HER2-positive human gastric cancer xenograft models.
Yamashita-Kashima Y; Iijima S; Yorozu K; Furugaki K; Kurasawa M; Ohta M; Fujimoto-Ouchi K
Clin Cancer Res; 2011 Aug; 17(15):5060-70. PubMed ID: 21700765
[TBL] [Abstract][Full Text] [Related]
11. Effects of a human compact anti-ErbB2 antibody on gastric cancer.
Fedele C; Carvalho S; Riccio G; Paciello R; Laccetti P; Schmitt F; De Lorenzo C
Gastric Cancer; 2014 Jan; 17(1):107-15. PubMed ID: 23460348
[TBL] [Abstract][Full Text] [Related]
12. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models.
Scheuer W; Friess T; Burtscher H; Bossenmaier B; Endl J; Hasmann M
Cancer Res; 2009 Dec; 69(24):9330-6. PubMed ID: 19934333
[TBL] [Abstract][Full Text] [Related]
13. A Novel Anti-HER2 Bispecific Antibody With Potent Tumor Inhibitory Effects
Mohammadi M; Jeddi-Tehrani M; Golsaz-Shirazi F; Arjmand M; Bahadori T; Judaki MA; Shiravi F; Zare HA; Haghighat FN; Mobini M; Amiri MM; Shokri F
Front Immunol; 2020; 11():600883. PubMed ID: 33679691
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic reovirus combined with trastuzumab enhances antitumor efficacy through TRAIL signaling in human HER2-positive gastric cancer cells.
Hamano S; Mori Y; Aoyama M; Kataoka H; Tanaka M; Ebi M; Kubota E; Mizoshita T; Tanida S; Johnston RN; Asai K; Joh T
Cancer Lett; 2015 Jan; 356(2 Pt B):846-54. PubMed ID: 25444894
[TBL] [Abstract][Full Text] [Related]
15. A monoclonal antibody targeting ErbB2 domain III inhibits ErbB2 signaling and suppresses the growth of ErbB2-overexpressing breast tumors.
Meng Y; Zheng L; Yang Y; Wang H; Dong J; Wang C; Zhang Y; Yu X; Wang L; Xia T; Zhang D; Guo Y; Li B
Oncogenesis; 2016 Mar; 5(3):e211. PubMed ID: 26999718
[TBL] [Abstract][Full Text] [Related]
16. Novel drug delivery liposomes targeted with a fully human anti-VEGF165 monoclonal antibody show superior antitumor efficacy in vivo.
Shi C; Cao H; He W; Gao F; Liu Y; Yin L
Biomed Pharmacother; 2015 Jul; 73():48-57. PubMed ID: 26211582
[TBL] [Abstract][Full Text] [Related]
17. Enhanced sensitization to taxol-induced apoptosis by herceptin pretreatment in ErbB2-overexpressing breast cancer cells.
Lee S; Yang W; Lan KH; Sellappan S; Klos K; Hortobagyi G; Hung MC; Yu D
Cancer Res; 2002 Oct; 62(20):5703-10. PubMed ID: 12384528
[TBL] [Abstract][Full Text] [Related]
18. Anti-cancer activity of anti-p185HER-2 ricin A chain immunotoxin on gastric cancer cells.
Zhou XX; Ji F; Zhao JL; Cheng LF; Xu CF
J Gastroenterol Hepatol; 2010 Jul; 25(7):1266-75. PubMed ID: 20594254
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-125a-5p is an independent prognostic factor in gastric cancer and inhibits the proliferation of human gastric cancer cells in combination with trastuzumab.
Nishida N; Mimori K; Fabbri M; Yokobori T; Sudo T; Tanaka F; Shibata K; Ishii H; Doki Y; Mori M
Clin Cancer Res; 2011 May; 17(9):2725-33. PubMed ID: 21220473
[TBL] [Abstract][Full Text] [Related]
20. Granulocyte-colony stimulating factor upregulates ErbB2 expression on breast cancer cell lines and converts primary resistance to trastuzumab.
Cavalloni G; Sarotto I; Pignochino Y; Gammaitoni L; Migliardi G; Sgro L; Piacibello W; Risio M; Aglietta M; Leone F
Anticancer Drugs; 2008 Aug; 19(7):689-96. PubMed ID: 18594210
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
